Archives for June 14th, 2018
Keytruda becomes first anti-PD-1 therapy for patients with advanced cervical cancer
Custom Synthesis, The US Food and Drug Administration approved Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic cervical cancer with disease progression on or...
Santhera Pharmaceuticals submits NDA in South Korea
Custom Synthesis, Santhera Pharmaceuticals said on Tuesday that the Korean Ministry of Food and Drug Safety (MFDS) has accepted its new drug application (NDA) for...
4D pharma cleared to study Blautix
Custom Synthesis, 4D pharma has been cleared by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Products Regulatory Authority (HPRA) to kick...
TiGenix’s CEO leaves as operations integrate into Takeda
Custom Synthesis, TiGenix NV’s Chief Executive Officer, Eduardo Bravo will depart the board of directors and his role as CEO of TiGenix effective as...